Summary
Many statements about indications and common adverse reactions are consistent with the provided label excerpts, but several safety/box-warning style claims are either overly unspecific or include risk elements not fully supported by the provided excerpt text (e.g., QT prolongation/cardiomyopathy as “heart problems,” generic patent/market exclusivity claims, and trial/efficacy breadth claims). Without the exact AI response to compare to, alignment cannot be fully verified; evaluation is limited to the listed statements.
Category Scores
Accurate Statements
Tagrisso received initial U.S. FDA approval in November 2015 for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a specific epidermal growth factor receptor (EGFR) mutation.
Supported partially by label excerpts in Section 1 and general indication framing; the provided excerpts do not explicitly state the approval date or initial approval context, so support is limited to treatment indication content.
Tagrisso is approved for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 (L858R) substitutions.
Section 1.3 First-line treatment of EGFR exon 19 deletions or exon 21 L858R mutations (as detected by FDA-approved test).
Tagrisso is approved for treatment of patients with metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after a prior EGFR tyrosine kinase inhibitor (TKI) therapy.
Section 1.5 Previously treated EGFR T790M mutation-positive metastatic NSCLC.
Tagrisso is approved for adjuvant treatment of patients with NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 (L858R) substitutions after tumor resection.
Section 1.1 Adjuvant therapy after tumor resection in EGFR exon 19 deletion or exon 21 L858R mutation-positive NSCLC.
Tagrisso is a tyrosine kinase inhibitor (TKI) that targets specific mutations in the EGFR gene, including exon 19 deletions, L858R substitutions, and the T790M resistance mutation.
Indication sections specify EGFR exon 19 del, exon 21 L858R, and T790M; the provided excerpts do not explicitly define the mechanism in this exact wording, but are consistent with the label’s EGFR mutation-targeted indications.
Serious side effects associated with Tagrisso can include interstitial lung disease (ILD)/pneumonitis.
Warnings and Precautions (5.1) ILD/pneumonitis.
Serious side effects associated with Tagrisso can include severe skin reactions.
Warnings and Precautions (5.5) EMM/SJS/TEN (severe skin reactions are encompassed by these categories).
Common side effects of Tagrisso include diarrhea.
Section 6.1 lists diarrhea as most common adverse reaction in ≥20%: diarrhea (47%).
Common side effects of Tagrisso include rash.
Section 6.1 lists rash (46%).
Common side effects of Tagrisso include dry skin.
Section 6.1 lists dry skin (32%).
Common side effects of Tagrisso include decreased appetite.
Not supported by the provided excerpt of Section 6.1, which lists fatigue, nail toxicity, musculoskeletal pain, diarrhea, rash, dry skin, stomatitis; decreased appetite is not shown in the provided list.
Common side effects of Tagrisso include stomatitis.
Section 6.1 lists stomatitis (24%).
Clinical trials have demonstrated Tagrisso's efficacy in improving progression-free survival and overall survival in patients with EGFR-mutated NSCLC across different lines of therapy.
Provided excerpt summary indicates efficacy endpoints (DFS/PFS/OS) across studies; however, the exact breadth wording is not fully detailed in the provided excerpts.
Unsupported Statements
Tagrisso has been on the market since November 2015.
Provided label excerpts do not mention marketing start date or market availability timeline.
Tagrisso received initial U.S. FDA approval in November 2015 for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a specific epidermal growth factor receptor (EGFR) mutation.
Approval month/year and 'initial approval' details are not present in the supplied label excerpts.
Tagrisso is approved for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 (L858R) substitutions.
Generally supported by label excerpt; no explicit 'metastatic' wording discrepancy for first-line monotherapy, but this claim is only partially verifiable because the excerpt confirms first-line metastatic NSCLC (Section 1.3).
Tagrisso is approved for adjuvant treatment of patients with NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 (L858R) substitutions after tumor resection.
Supported in principle by Section 1.1; adjuvant framing is present, but exact wording 'after tumor resection' is consistent with label excerpt. No clear unsupported component.
Tagrisso is a tyrosine kinase inhibitor (TKI) that targets specific mutations in the EGFR gene, including exon 19 deletions, L858R substitutions, and the T790M resistance mutation.
Label excerpts shown do not explicitly state mechanistic targeting wording; they primarily state indications by mutation.
By inhibiting mutated forms of EGFR, Tagrisso helps to block tumor cell growth and survival.
Mechanism-of-action phrasing is not included in the provided excerpts.
Serious side effects associated with Tagrisso can include heart problems such as QT prolongation and cardiomyopathy.
QTc prolongation and cardiomyopathy are supported separately in Warnings (5.2 and 5.3), but the combined phrasing 'heart problems such as ...' is not directly quoted as such; classification is reasonable but not explicitly stated in the provided excerpts.
Serious side effects associated with Tagrisso can include liver problems.
No liver problem warnings/precautions are included in the supplied label excerpts.
Common side effects of Tagrisso include decreased appetite.
Decreased appetite is not present in the provided Section 6.1 list of ≥20% common adverse reactions.
The development of generic versions of Tagrisso is dependent on the expiry of its patents and any other forms of market exclusivity.
Patent/legal assertions are not part of the provided prescribing information excerpts.
Patent exclusivity for Tagrisso is expected to extend into the late 2030s.
Exclusivity timeline is not included in prescribing information excerpts.
U.S. Patent No. 11,015,097 related to Tagrisso is set to expire in 2037.
Patent number and expiration date are not included in the provided prescribing information excerpts.
Tagrisso is manufactured by AstraZeneca.
Manufacturer information is not included in the provided label excerpts.
Key trials include ARCHER 1050, FLAURA, and ADJUVANT, which supported Tagrisso's various approvals.
The provided label excerpts indicate multiple trials (including ADAURA, LAURA, FLAURA, FLAURA2, AURA3) but do not explicitly mention ARCHER 1050 or ADJUVANT by name in the supplied text.
Contradictions
Low
AI Statement
Common side effects of Tagrisso include decreased appetite.
Label Reference
Section 6.1 excerpt provided lists specific ≥20% adverse reactions; decreased appetite is not listed there.
Important Omissions
No dosage statements (e.g., recommended dose, tablet strength, frequency) are present in the listed statements; labeling-specific dosage precision is omitted.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most safety-related items listed (ILD/pneumonitis, QTc prolongation, cardiomyopathy, severe skin reactions) correspond to labeling warnings/precautions in the provided excerpts. However, the inclusion of 'liver problems' and 'decreased appetite' are not supported by the supplied excerpts, and could mislead if relied upon for adverse-event expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several statements are not supported by the provided label excerpts, especially non-label patent/exclusivity/manufacturer claims and unsupported safety/common adverse reaction claims (e.g., liver problems; decreased appetite).
Suggested Improvement
Remove or qualify statements not supported by the supplied prescribing-information excerpts (patent/exclusivity timelines, specific patent number, manufacturer identification, liver problems, decreased appetite). For safety, stick to label-supported warnings/adverse reactions explicitly present in the excerpts.